Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 237,998,145 papers from all fields of science
Search
Sign In
Create Free Account
Macitentan
Known as:
Macitentanum
, N-(5-(4-Bromophenyl)-6-(2-((5-Bromopyrimidin-2-Yl)Oxi)Ethoxy)Pyrimidin-4-Yl)-N'-Propylsulfuric Diamide
, N-(5-(4-bromophenyl)-6-(2-(5-bromopyrimidin-2-yloxy)ethoxy)pyrimidin-4-yl)-N'-propylaminosulfonamide
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
8 relations
Narrower (3)
ACT 064992
Actelion-1
Opsumit
Broader (4)
Endothelin A Receptor Antagonists
Endothelin B Receptor Antagonists
Pyrimidines
Sulfonamides
Macitentan 10 MG Oral Tablet [Opsumit]
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
What added value do these compounds bring ? New compounds for the treatment of pulmonary hypertension
R. Hullin
2018
Corpus ID: 56283032
Pulmonary hypertension (PH) was reported for the first time in 1891 when the autopsy of a patient with sudden death revealed…
Expand
2017
2017
Abstract 11694: 6-minute Walk Test Distance After Bosentan to Macitentan Switch in Adult Outpatients With Group 1 Pulmonary Hypertension: A Multicenter Retrospective Cohort
N. Caruso
,
M. T. Politi
,
+6 authors
G. Bortman
2017
Corpus ID: 80806663
Introduction: Endothelin receptor antagonists (ERA) have shown to be beneficial in improving clinical, haemodynamic and…
Expand
2017
2017
Transitioning pulmonary arterial hypertension patients from bosentan to macitentan: efficacy and safety data
Mário Santos
,
F. Gonçalves
,
L. Carvalho
,
A. Reis
2017
Corpus ID: 80147140
Introduction: In addition to several pharmacodynamics advantages over bosentan, macitentan has once-a-day profile, less liver…
Expand
2015
2015
RP-HPLC METHOD DEVELOPMENT AND VALIDATION FOR ESTIMATION OF MACITENTAN IN TABLET DOSAGE FORM.
M. Ahmed
,
S. Shetty
2015
Corpus ID: 97736317
The objective of the current study was to develop a simple, accurate, precise and rapid RP-HPLC method with subsequently validate…
Expand
Review
2015
Review
2015
A Comprehensive Drug Review on Macitentan: A Preeminent Inclusion to Pulmonary Arterial Hypertension Therapy
Dherya Bahl
,
Rakesh Jaiswal
,
+7 authors
Shahalam Khan
2015
Corpus ID: 39577672
Macitentan is a radically novice oral orphan drug which was approved by FDA in Oct 2013 (under trade name Opsumit®). It belongs…
Expand
2014
2014
DEVELOPMENT AND VALIDATION OF RP-HPLC-PDA METHOD FOR THE ESTIMATION OF MACITENTAN IN BULK AND TABLET DOSAGE FORMS.
A. Unnisa
,
S. S. Ali
,
Santosh Kumar.S
2014
Corpus ID: 51847757
Article history The aim of the present study was to develop RP-HPLC-PDA method for the estimation of Macitentan in bulk and…
Expand
2014
2014
ACT-064992 crystal and preparation method thereof, its pharmaceutical composition and purposes
Hai-Ping Lao
,
Xiao-Xia Sheng
,
Xiaohong Sheng
2014
Corpus ID: 220469990
The present invention relates to the novel crystal forms of ACT-064992, described novel crystal forms has dominance aspect…
Expand
Review
2013
Review
2013
Review of idiopathic pulmonary fibrosis diagnosis and management recommendations in Europe
A. Xaubet
,
J. Behr
,
E. Bendstrup
,
V. Cottin
2013
Corpus ID: 79146683
Increased knowledge of Idiopathic Pulmonary Fibrosis (IPF) led to the development of evidence-based diagnosis and treatment…
Expand
2012
2012
Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Dual Endothelin Receptor Antagonist, in Subjects With Severe Renal Function Impairment
P. Sidharta
,
N. Lindegger
,
I. Ulč
,
Paul van Giersbergen
,
J. Dingemanse
2012
Corpus ID: 71230185
Background The orally active dual endothelin receptor antagonist aprocitentan targets a novel pathway in the treatment of…
Expand
2009
2009
Therapeutic compositions containing macitentan
马丁尼·克劳泽
2009
Corpus ID: 92034364
The invention relates to a product containing the compound of formula (I) below or a pharmaceutically acceptable salt of this…
Expand